SANTA BARBARA, Calif., June 17, 2022 /PRNewswire/ — Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, will present details on its R&D pipeline combining wearable delivery devices with subcutaneous formulation technology at two investor events this month. First, co-founder and Chief Science…

Source

Previous articleDelix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank
Next articleMindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin